Keywords
Proteus mirabilis
immunomodulater activity
cytokine
Liposome (LIP)
Abstract
Proteus mirabilis is a common cause of recurrent urinary tract infections in individuals with functional or structural abnormalities. It also forms bladder and kidney stones. Lipopolysaccharide (LPS) is a potential Proteus virulence factor that plays a key role in pathogenesis, as well as in stimulating innate immune response. Therefore, this study aimed to extract LPS from a highly resistant isolate and incorporate it in a delivery system (liposome) to stimulate an immune response against virulent pathogens. In the work, 50 isolates of P. mirabilis were taken from 200 urine specimens obtained from recurrent-urinary tract infections (UTI) of patients of AL-Sadar Hospital. Specimens were cultured on specific media, and then bacterial isolates were identified via morphological, biochemical and Vitek-2 systems. The results showed that P. mirabilis was expressed in 11 (22%), 30 (60%) and 9 (18%) recurrent UTI, kidney stone and catheter samples, respectively. All isolates were assessed through antibiogram testing, with the results revealing that most isolates were multidrug resistant to more than 3 classes of antibiotics. Herein, P. mirabilis NO 50 revealed particularly high resistance, so it was chosen for LPS extraction. Lethal dose 50 (LD50) observations indicated that a live suspension of P. mirabilis was at 4.5×107 CFU/ml, while LPS was at 270 μg/ml. LPS was used as an immunogenic to stimulate the immune system through injecting Rats intraperitoneally (I.P.) with 1 ml of LD50%. Subsequently, the efficiency of immunogenes in stimulating the immune response was evaluated by determining the Toll-like receptor and CD14 levels. The results indicate that LPS incorporated in the Liposome released moderate levels of Toll-like receptors-4 (TLR4) that enabled the immune system to clear pathogens. The LPS+ complete Freund’s adjuvant (CFA) and LPS vaccinated groups recorded hyper production for TLR4 (52.2 and 40.9 pg/ml, respectively), this was followed by liposome (LIP) and bacterial suspension (11 and 20.5 pg/ml, respectively) in ranking effectiveness. This study reveals a mean of CD14 that was higher in both LPS and LPS+CFA
and moderate in LPS+LIP, in comparison with control and liposome groups.
In conclusion, LPS-Liposomes are a promising nanomedicine for modulating the hyper response of LPS. This may lead to tissue inflammation but appeared beneficial in stimulating the immune response at moderate levels so as to eradicate infection without tissue damage.
References
1. Hegazy WAH. Diclofenac inhibits virulence of Proteus mirabilis isolated from diabetic foot ulcer. Afr J Microbiol. Res. 2016;10:733-43.
2. Schaffer JN, Pearson MM. Proteus mirabilis and urinary tract infections. J Microbiol Spect. 2015;3(5).
3. Brzozowska E, Pyra A, Pawlik K, Janik M, Górska S., Urbańska N. Hydrolytic activity determination of tail tubular Protein A of Klebsiella pneumoniae bacteriophages towards saccharide substrates. J Sci Rep. 2017;7(1):18048.
4. Brotzki CR, Mergenhagen KA,, Bulman ZP, Tsuji BT, Berenson ChS. Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing. BMJ Case Rep. 2016;bcr2016215956.
5. Wang Y, Zhang S, Yu J, Zhang H, Yuan Z, Sun Y, Song H. An outbreak of Proteus mirabilis food poisoning associated with eating stewed pork balls in brown sauce, Beijing. J Food Control. 2010; 21(3):302-5.
6. Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. J Infection. 2010;38(1): 41-6.
7. NakanoR, Nakano A, Abe M, Inoue M, Okamoto R. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan. J Med Microbiol. 2012;61(12):1727-35.
8. Nagano N, Shibata N, Saitou Y, Nagano Y, Arakawa Y. Nosocomial outbreak of infections by Proteus mirabilis that produce Extended – spectrum CTX-M-2 type β-lactamase. J Clin Microbiol. 2003;41(12): 5530-6.
9. Jain S, Gaind R, Kothari C, Sehgal R, Shamweel A, Thukral SS, et al. VEB-1 extended-spectrum β-lactamase-producing multidrug-resistant Proteus mirabilis sepsis outbreak in a neonatal intensive care unit in India: clinical and diagnostic implications. JMM Case Rep. 2016;3(4): e005056. doi: 10.1099/jmmcr.0.005056.
10. Rogan D, Babiuk LA. Novel vaccines from biotechnology. J Rev Sci Tech. 2005;24(1):159-74.
11. Kim D, Heajun JH, Lim L, Kyung MW, Hyun MR, Shik G, et al. N-acetyl cysteine Prevents LPS induced pro-inflammatory cytokines and MMP2 Production in Gingival fibroblast. Arch Pharm Res. 2007; 30(10):1283-92.
12. Darweesh MF. Molecular characterization of ESBL gene in Citrobacter spp. and antibacterial activity of omega-3 against resistant isolates. Curr Issues Phar Med Sci. 2017;30(3):156-61.
13. Christensen D, Korsholm KS, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. J Expert Review Vacc. 2011;10(4): 513-21.
14. Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. J Adv Pharm Bull. 2017;7(1):3.
15. Naser HH, Salih SM, Al-Shaibani AB. Protective humoral immunity induced by lipopolysaccharide incorporated liposome in mice against shigellaflexneri infection. J Al-Nahrain Univ. 2013; 16(3):205-13.
16. Miernikiewicz P, Kłopot A, Soluch R, Szkuta P, Kęska W, Hodyra-Stefaniak K, et al. T4 phage tail adhesin gp12 counteracts LPS-induced inflammation in vivo. J. Frontiers Microbiol. 2016;7:1112.
17. Dharmadhikari SM, Peshwe AS. Molecular level studies on multiple antibiotic and serum resistance in UTI pathogens. Indian J Biotechnol. 2009;8:40-5.
18. Silipo A, Lanzetta R, Amoresano A, Parrilli M, Moliaro A. Ammonium hydroxide hydrolysis: a valuable support in the MALDI-TOF mass spectrometry analysis of lipid A fatty acid distribution. J Lipid Res. 2002;43:2188-95.
19. Chandan V, Fraser AD. Simple extraction of Campylobacter lipopolysaccharide and protein antigens and production of their antibodie in egg yolk. Inter L Food Microbiol. 1994;22:189-200.
20. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Determination of sugars and related substances. J Anal Chem. 1956;28: 350-35621
21. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem. 1976;72:248-254.
22. Xianguo H, Ursula M. Antifungal compound from Solanum nigrescens. J Ethanopharm. 1994;43:173-7.
23. Reed LJ, Muench HA. simple method of estimation fifty percent end points. Am J Hyg. 1938;27:493-8.
24. Alui Y, Nwude N. Determination of the medin lethal dose (LD 50) In: Velerenary Pharmacology and Toxicology Experiments. J. Baraka Press Zaria; 1982:104-22.
25. Rittig MG, Kaufmann A, Robins A, Shaw B, Sprenger H, Gemsa D, et al. Smooth and rough lipopolysaccharide phenotypes of Brucella induce different intracellular trafficking and cytokine/chemokine release in human monocytes. J Leuk Biol. 2003;74(6):1045-55.
26. Malik SN. Study the effect of polysaccharide extracted from Proteus merabilis in protect UTI in animal lab. Master thesis - Baghdad Uni. College of science. (In Arabic) 2006.
27. Lan F, Yue X, Ren G, Wang Y, Xia T. Serum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC. Inter J Clin Exper Path. 2014;7(11):8087.
28. Ghosh C, Bishayi B. Characterization of toll-like receptor-4 (TLR-4) in the spleen and thymus of Swiss Albino mice and its modulation in experimental endotoxemia. J Immunol Res. 2015.
29. MacRae S, Herman C, Stulting RD, Lippman R, Whipple D, Cohen E, Phillips D. Corneal ulcer and adverse reaction rates in premarket contact lens studies. AmJ Ophthal. 1991;111(4):457-465.
30. Watanabe S, Kumazawa Y, Inoue J. Liposomal lipopolysaccharide initiates TRIF-dependent signaling pathway independent of CD14. PLoS One. 2013;8(4), e60078.
31. Heldwein KA, Fenton MJ. The role of Toll-like receptors in immunity against mycobacterial infection. Microb Infect. 2002;4(9):937-44.
32. Stils Jr, Harold F. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. J. ILAR46. 2005;3:280-293.
33. Karananou P, Fleva A, Tramma D, Alataki A, Pavlitou-Tsiontsi A, Emporiadou-Peticopoulou M, Papadopoulou-Alataki E. Altered expression of TLR2 and TLR4 on peripheral CD14+ blood monocytes in children with urinary tract infection. BioMed Res Inter. 2016.
34. Landmann R, Knopf HP, Link S, Sansano S, Schumann R, Zimmerli W. Human monocyte CD14 is upregulated by lipopolysaccharide. J Infect Immun. 1996;64(5):1762-9.
35. Stewart EC, McIntosh TJ, Poxton, IR.The biological activity of a liposomal complete core lipopolysaccharide vaccine. J Endotoxin Res. 2002;8(1):39-46.
36. O’Hagan TD, Friedland LR, Hanon E, Didierlaurent AM. Towards an evidence based approach for the development of adjuvanted vaccines. Curr Opin Immunol. 2017;47:93-102.
37. Abid AJ, Alwan SJ. Role of T regulatory cells with valvular heart disease. Res J Pharm Biol Chem Sci. 2016;7(3):1473-8.
38. Khadhim MM, Al-Hajjiah NN, Shaheed OM. Detection of the CD64 on neutrophils and CD69 on lymphocytes by flowcytometry as a marker for early diagnosis of neonatal sepsis. Sepsis, 2015;8:9.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2019 Autors